External validation of the UCSF-CAPRA (university of California, San Francisco, cancer of the prostate risk assessment) in japanese patients receiving radical prostatectomy

Japanese Journal of Clinical Oncology

Volumn 41, Issue 11, 2011, Pages 1259-1264

  Ishizaki, Fumio ^a   Hoque, Aminul ^a   Nishiyama, Tsutomu ^a   Kawasaki, Takashi ^b   Kasahara, Takashi ^a   Hara, Noboru ^a   Takizawa, Itsuhiro ^a   Saito, Toshihiro ^b   Kitamura, Yasuo ^b   Akazawa, Kohei ^a   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

D'Amico risk classification; Radical prostatectomy; UCSF CAPRA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER STAGING; D' AMICO RISK CLASSIFICATION; GLEASON SCORE; HUMAN; JAPAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT OUTCOME; TUMOR BIOPSY; UNIVERSITY OF CALIFORNIA SAN FRANCISO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE; VALIDATION PROCESS;

ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SAN FRANCISCO; SURVIVAL RATE;

EID: 80155170238     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr136     Document Type: Article

References (19)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Matsuda T, Marugame T, Kamo KI, Katanoda K, Ajiki W, Sobue T. The Japan Cancer Surveillance Research Group. Cancer Incidence and Incidence Rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 2011;41:139-47.
3. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007;178:S14-9.
4. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D'Amico risk classification of prostate cancer. Urology 2007;70:931-5.
5. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
6. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
7. D'Amico AV. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Williston Park) 2001;15:1049-59.
8. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 2005;173:1126-31.
9. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:1164-72.
10. D'Amico AV, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;49:679-84.
11. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173:1938-42.
12. May M, Knoll N, Siegsmund M, Fahlenkamp D, Volgler H, Hoschke B, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1,296 patients. J Urol 2007;178: 1957-62.
13. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology 2008;72:396-400.
14. Loeb S, Carvalhal GF, Kan D, Desai A, Catalona WJ. External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Urol Oncol 2010;Sep 3 [Epub ahead of print].
15. Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
16. Kuroiwa K, Uchino H, Yokomizo A, Naito S. Impact of reporting rules of biopsy Gleason score for prostate cancer. J Clin Pathol 2009;62: 260-3.
17. Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
18. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Jr, Amling CL, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006;107:2384-91.
19. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009;101:878-87.